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A B S T R A C T
Background: Tofacitinib is an oral Janus kinase inhibitor.
Objective: This study assessed tofacitinib efﬁcacy and safety vs placebo in Asian patients with moderate to
severe chronic plaque psoriasis.
Methods: Patients from China mainland, Taiwan, and Korea were randomized 2:2:1:1 to tofacitinib 5 mg
(N = 88), tofacitinib 10 mg (N = 90), placebo ! 5 mg (N = 44), or placebo ! 10 mg (N = 44), twice daily (BID)
for 52 weeks. Placebo-treated patients advanced to tofacitinib at Week 16. Co-primary efﬁcacy
endpoints: proportions of patients achieving Physician’s Global Assessment (PGA) response (‘clear’ or
‘almost clear’) and proportion achieving 75% reduction from baseline Psoriasis Area and Severity Index
(PASI75) at Week 16.
Results: At Week 16, more patients achieved PGA and PASI75 responses with tofacitinib 5 mg (52.3%;
54.6%) and 10 mg (75.6%; 81.1%) BID vs placebo (19.3%; 12.5%; all p < 0.0001). Of patients with a Week 16
response, 73.6% and 75.0% maintained PGA response, and 76.8% and 84.9% maintained PASI75 to Week 52
with tofacitinib 5 mg and 10 mg BID, respectively. Over 52 weeks, 2.2–4.5% of patients across treatment
groups experienced serious adverse events, and 1.1–6.8% discontinued due to adverse events.
Conclusion: Tofacitinib demonstrated efﬁcacy vs placebo at Week 16 in Asian patients with moderate to
severe plaque psoriasis; efﬁcacy was maintained through Week 52. No unexpected safety ﬁndings were
observed. [NCT01815424]
© 2017 The Authors and Pﬁzer Inc. Published by Elsevier Ireland Ltd. on behalf of Journal of
Dermatological Science. All rights reserved. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Plaque psoriasis is a chronic inﬂammatory disease, which
impacts both patients’ physical health and quality of life [1].
Psoriasis is a global disease, with approximately 2–4% of European
and North American populations affected [2], although the
prevalence of psoriasis is generally lower in East Asia (e.g. 0.2%
in Taiwan [3], 0.3% in Korea [4], and 0.47% in China mainland [5]).
However, differences in disease manifestation, treatment efﬁcacy,
and adverse events (AEs) have been noted in clinical trials in East
Asian populations compared with other regions; therefore, it is
important to assess psoriasis treatments speciﬁcally in this region
[6].
Tofacitinib is an oral Janus kinase inhibitor. The efﬁcacy and
safety of tofacitinib 5 mg and 10 mg twice daily (BID) in patients
with moderate to severe chronic plaque psoriasis has been
demonstrated in Phase 2 [7] and global Phase 3 [8–11] trials of
up to 56 weeks’ duration, and in a long-term extension study with
efﬁcacy endpoints reported through 24 months and safety
reported over 33 months of exposure [11]. The efﬁcacy and safety
of tofacitinib has also been studied in several immune-mediated
inﬂammatory diseases, including rheumatoid arthritis (RA) [12–
17], psoriatic arthritis (NCT01877668, NCT01882439,
NCT01976364), ankylosing spondylitis [18], Crohn’s disease [19]
(NCT01393626, NCT01393899, NCT01470599), and ulcerative
colitis [20,21].
Here, we report the efﬁcacy and safety of tofacitinib vs placebo
for the treatment of moderate to severe chronic plaque psoriasis in
East Asian patients.
2. Materials and methods
2.1. Patients
Patients were enrolled from multiple dermatology centers in
China mainland, Taiwan, and Korea. Patient inclusion and
exclusion criteria were similar to those of previous global studies
[10,11]. Full details are provided in the Supplementary Methods.
Brieﬂy, patients were aged 18 years with a diagnosis of plaque-
type psoriasis for 12 months at screening, covering 10% of their
body surface area (BSA), with a Psoriasis Area and Severity Index
(PASI) score 12 and Physician’s Global Assessment (PGA) score of
‘moderate’ or ‘severe’ at baseline.Randomization
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Fig. 1. Study design.
aWeek 16–52 were double-blind with respect to dose of tofacitinib. BID, twice daily; N2.2. Study design
This was a Phase 3, randomized, double-blind, placebo-
controlled, parallel-group study (NCT01815424) carried out
between December 2013 and July 2015 (Fig. 1). A computer-
generated randomization schedule was developed by Pﬁzer and an
automated telephone/web-based interactive response system was
used to assign patients 2:2:1:1 to receive tofacitinib 5 mg BID,
tofacitinib 10 mg BID, placebo advanced to tofacitinib 5 mg BID, or
placebo advanced to tofacitinib 10 mg BID. At Week 16, patients
initially receiving placebo were automatically advanced to their
pre-determined tofacitinib dose. Patients were treated up to Week
52. Patients, investigators, and the sponsor were blinded to study
treatment. Placebo was provided as oral tablets matching those of
tofacitinib.
The study was reviewed by the institutional review board and
independent ethics committees of each study center, and was
conducted in accordance with the International Conference on
Harmonisation guidelines on Good Clinical Practice and applicable
local regulatory requirements and laws. Patients provided
informed consent prior to study participation.
2.3. Outcomes
The primary endpoints were the proportion of patients
achieving a PGA response (PGA of ‘clear’ or ‘almost clear’ on a
5-point scale: 0 = clear; 4 = severe), and the proportion of patients
achieving 75% improvement from baseline PASI (PASI75 re-
sponse) at Week 16.
Key secondary endpoints included: % change from baseline
(CFB) in BSA at Week 16; proportion of patients achieving 90%
improvement from baseline PASI (PASI90) at Week 16; CFB in
Dermatology Life Quality Index (DLQI) total score at Week 16; PGA
response at Week 4; PASI75 at Week 4; CFB in DLQI at Week 4; %
CFB in Nail Psoriasis Severity Index (NAPSI) at Week 16 among
patients with nail psoriasis at baseline; and the proportion of
patients maintaining PGA, PASI75, or PASI90 responses at Week 52,
among those with a corresponding Week 16 response. Other
secondary endpoints included the median time to achieve PGA or
PASI75 responses up to Week 16, and PGA or PASI75 responses at
each study visit through Week 52.
Safety was assessed through spontaneous reporting of AEs,
physical examinations, and clinical laboratory tests. AEs of specialWeeks
Double-blinda, 
active only
Tofacitinib 5 mg BID
Tofacitinib 10 mg BID
Tofacitinib 5 mg BID
Tofacitinib 10 mg BID
32 40 52
, number of patients randomized to treatment.
Fig. 2. Summary of patient disposition through Week 52.
BID, twice daily; W, week.
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herpes zoster infections; malignancies; major adverse cardiovas-
cular events (MACE); and gastrointestinal perforations.
2.4. Statistical analysis
A sample size of 70 Chinese patients per group was determined
to give 94% power to achieve a statistical signiﬁcance level of 0.05
using a two-sided test for the comparisons of tofacitinib 5 mg andTable 1
Patient demographics and baseline characteristics.
Tofacitinib 5 m
Male, n (%) 65 (73.9) 
Age, mean (SD) [years] 40.7 (11.3) 
BMI, mean (SD) [kg/m2] 25.5 (4.0) 
Region, n (%)
China mainland 74 (84.1) 
Taiwan 8 (9.1) 
Korea 6 (6.8) 
Current smoker, n (%) 36 (40.9) 
Duration of psoriasis, mean (SD) [years] 15.6 (9.5) 
PASI score, mean (SD) 25.3 (10.2) 
% affected BSA, mean (SD) 37.4 (19.6) 
PGA, n (%)
Moderate 77 (87.5) 
Severe 11 (12.5) 
DLQI score, mean (SD) 13.5 (7.3) 
Presence of psoriatic arthritis, n (%) 6 (6.8) 
Presence of nail psoriasis, n (%) 38 (43.2) 
Previous exposure to systemic treatment, n (%)b 49 (55.7) 
Previous use of biologics, n (%)c 17 (19.3) 
Inadequate responsed or intolerant to systemic therapies,e n (%) 38 (43.2) 
BID, twice daily; BMI, body mass index; BSA, body surface area; DLQI, Dermatology L
Assessment; PUVA, psoralen combined with ultraviolet A treatment; SD, standard dev
a Placebo group includes patients randomized to placebo ! tofacitinib 5 mg BID and
b Includes conventional, biologics, phototherapy (PUVA or non-PUVA) or traditional 
c Includes adalimumab, etanercept, inﬂiximab, or ustekinumab; regardless of previo
d Discontinued due to lack of efﬁcacy.
e Includes ciclosporin, methotrexate, methotrexate sodium, methylprednisolone, acitr
or tripterygium glycosides.10 mg BID vs placebo for both primary endpoints. Further details
are provided in the Supplementary Methods.
Data were analyzed for the full analysis set: all randomized
patients who received 1 dose of study drug. All binary data,
including the primary endpoints, were analyzed using Cochran-
Mantel Haenszel statistics adjusting for the effect of site, with non-
responder imputation for missing data. To preserve overall Type I
error for the primary analysis, a step-down approach was used for
superiority vs placebo in the following order: PGA response withg BID N = 88 Tofacitinib 10 mg BID
N = 90
Placeboa N = 88 Total N = 266
67 (74.4) 62 (70.5) 194 (72.9)
41.0 (12.0) 41.7 (13.7) 41.1 (12.3)
25.1 (4.2) 25.2 (3.5) 25.3 (3.9)
74 (82.2) 74 (84.1) 222 (83.5)
10 (11.1) 9 (10.2) 27 (10.2)
6 (6.7) 5 (5.7) 17 (6.4)
35 (38.9) 35 (39.8) 106 (39.8)
14.4 (8.5) 13.2 (9.3) 14.4 (9.1)
25.3 (9.1) 26.1 (9.5) 25.6 (9.6)
36.4 (18.0) 35.8 (17.1) 36.5 (18.2)
77 (85.6) 67 (76.1) 221 (83.1)
13 (14.4) 21 (23.9) 45 (16.9)
14.1 (7.2) 12.3 (6.8) 13.3 (7.1)
4 (4.4) 8 (9.1) 18 (6.8)
40 (44.4) 38 (43.2) 116 (43.6)
46 (51.1) 48 (54.5) 143 (53.8)
14 (15.6) 8 (9.1) 39 (14.7)
34 (37.8) 38 (43.2) 110 (41.4)
ife Quality Index; PASI, Psoriasis Area and Severity Index; PGA, Physician’s Global
iation.
 placebo ! tofacitinib 10 mg BID.
Chinese medicine tripterygium glycoside.
us use of conventional systemic agents or phototherapy.
etin, isotretinoin, adalimumab, etanercept, inﬂiximab, ustekinumab, phototherapy,
Fig. 3. PGA (A) and PASI75 (B) responses with tofacitinib vs placebo at Week 16 (primary endpoint); and PGA (C) and PASI75 (D) responses through Week 52 by treatment
sequence (FAS NRI).
aNominal p value from post hoc analysis that was not type 1 error controlled. Placebo group includes patients randomized to placebo ! tofacitinib 5 mg BID and
placebo ! tofacitinib 10 mg BID. BID, twice daily; FAS, full analysis set; NRI, non-responder imputation; PASI75, 75% reduction in Psoriasis Area and Severity Index score
relative to baseline; PGA, Physician’s Global Assessment; SE, standard error; W, week.
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5 mg BID; PASI75 response with 5 mg BID. Statistical signiﬁcance
was claimed for a given endpoint at a given dose only if the prior
endpoint in the sequence met signiﬁcance requirements (p  0.05;
two-sided). A Breslow-Day test was performed to test the
homogeneity of the odds ratios across the investigational sites.
Investigational sites with <10 patients were pooled for this
analysis (16 individual study sites were combined into six pooled
sites). The differences in response proportions between each
tofacitinib dose and placebo with corresponding 95% conﬁdence
intervals were estimated based on the normal approximation.
Details of the statistical analysis for secondary endpoints,
including the step-down procedure used for the key secondary
endpoints, are provided in the Supplementary Methods. Within
each tofacitinib dose, statistical signiﬁcance was claimed for a
given endpoint if the prior endpoint in the step-down sequence
met signiﬁcance requirements (p  0.025, two-sided). Continuous
variables were analyzed using the data as observed with a mixed-
effect repeated measures model from which the least squares
mean of difference from placebo was derived.
3. Results
3.1. Patients
Of the 266 randomized patients, 244 (91.7%) completed Week
16 (tofacitinib 5 mg BID, n = 84 [95.5%]; 10 mg BID, n = 83 [92.2%];
placebo, n = 77 [87.5%]; Fig. S1), and 231 (86.8%) completed Week
52 (Fig. 2). Patient demographics and baseline characteristics were
similar across treatment groups, with the exception that the
placebo group included higher proportions of patients with severe
disease and biologic-naïve patients vs the tofacitinib groups
(Table 1).
3.2. Efﬁcacy
At Week 16, tofacitinib demonstrated superior efﬁcacy vs
placebo for both primary endpoints. PGA response was achieved by
52.3% and 75.6% of patients receiving tofacitinib 5 mg and 10 mg
BID, respectively, vs 19.3% with placebo (both p < 0.0001; Fig. 3A).
PASI75 was achieved by 54.6% and 81.1% of patients receiving
tofacitinib 5 mg and 10 mg BID vs 12.5% with placebo (both
p < 0.0001; Fig. 3B). There was no signiﬁcant difference in odds
ratio across (pooled) investigator sites for PGA response (Breslow-Table 2
Key secondary efﬁcacy endpoints (full analysis set).
Tofacitinib 5 mg B
N = 88
%CFB in affected BSA at Week 16, LSM (SE)b 54.4 (5.8)***
PASI90 response at Week 16, n (%)c 31 (35.2)***
CFB in DLQI score at Week 16, LSM (SE)b 7.0 (0.6)***
PGA response at Week 4, n (%)c 17 (19.3)***
PASI75 response at Week 4, n (%)c 4 (4.6) 
CFB in DLQI score at Week 4, LSM (SE)b 5.1 (0.5)yyy
%CFB in NAPSI score at Week 16, LSM (SE)b,d 15.0 (10.6) 
BID, twice daily; BSA, body surface area; CFB, change from baseline; DLQI, Dermatology
PASI75, 75% reduction in Psoriasis Area and Severity Index score relative to baseline; PA
PGA, Physician’s Global Assessment; SE, standard error.
* p < 0.025.
*** p < 0.0001 vs placebo in the step-down testing procedure.
yyy p < 0.0001 nominal signiﬁcance vs placebo.
a Placebo group includes patients randomized to placebo ! tofacitinib 5 mg BID and
b Mixed-effect repeated measures model, no imputation for missing values.
c P value for the Cochran-Mantel-Haenszel statistic controlling for (pooled) investiga
d Assessed in patients with nail psoriasis at baseline: tofacitinib 5 mg BID, n = 38; toDay test: 5 mg BID, p = 0.50; 10 mg BID, p = 0.69) or PASI75
(Breslow-Day test: 5 mg BID, p = 0.37; 10 mg BID, p = 0.51). The
median time to response was 8 weeks for both PGA and PASI75
responses with tofacitinib 10 mg BID, and 14 and 16 weeks,
respectively, with tofacitinib 5 mg BID (Table S1). Both PGA and
PASI75 responses were generally sustained from Week 16 through
Week 52 with tofacitinib 5 mg and 10 mg BID (Fig. 3C and D).
Based on the step-down testing procedure, patients receiving
tofacitinib 10 mg BID achieved signiﬁcant differences from placebo
(all p < 0.025) for all of the tested key secondary efﬁcacy endpoints
(Table 2). Patients in the tofacitinib 5 mg BID group achieved
signiﬁcant differences from placebo (all p < 0.025) for %CFB in BSA
at Week 16, PASI90 response at Week 16, CFB in DLQI at Week 16,
and PGA response at Week 4 (Table 2). Patients receiving tofacitinib
5 mg BID failed to achieve statistical signiﬁcance for two key
secondary endpoints: PASI75 at Week 4 and %CFB in NAPSI at Week
16 (both p > 0.025; Table 2); therefore, step-down testing was
stopped for all endpoints beyond PASI75 at Week 4; statistical
signiﬁcance could not be claimed for CFB in DLQI at Week 4 for
tofacitinib 5 mg BID.
Among patients treated with tofacitinib 5 mg and 10 mg BID
who achieved a Week 16 response, the majority maintained PGA
(73.6% and 75.0%, respectively), PASI75 (76.8% and 84.9%), and
PASI90 (70.5% and 74.1%) responses through Week 52 (Fig. 4).
3.3. Safety
3.3.1. Weeks 0–16
From baseline to Week 16, 64.8%, 67.8%, and 48.9% of patients
receiving tofacitinib 5 mg BID,10 mg BID, and placebo, respectively,
had treatment-emergent AEs of all causality (Table 3). Two
patients receiving tofacitinib 5 mg BID experienced serious AEs
(SAEs); no SAEs were reported in patients receiving tofacitinib
10 mg BID or placebo. The numbers of discontinuations due to AEs
were similar between treatment groups.
3.3.2. Weeks 0–52
From baseline to Week 52, patients receiving tofacitinib 5 mg
and 10 mg BID had similar rates of treatment-emergent AEs and
discontinuations due to AEs (all causality); the placebo to
tofacitinib groups also had generally similar rates of AEs from
Week 16 to Week 52 (Table 3). Four patients receiving tofacitinib
5 mg BID, two receiving tofacitinib 10 mg BID, and one patient who
advanced to tofacitinib 10 mg BID from placebo had SAEs.ID Tofacitinib 10 mg BID
N = 90
Placeboa
N = 88
73.8 (5.9)*** 2.3 (6.1)
54 (60.0)*** 3 (3.4)
9.1 (0.6)*** 1.6 (0.7)
34 (37.8)*** 1 (1.1)
22 (24.4)*** 0 (0.0)
6.0 (0.5)*** 0.9 (0.5)
33.3 (10.5)* 7.9 (12.0)
 Life Quality Index; LSM, least squares mean; NAPSI, Nail Psoriasis Severity Index;
SI90, 90% reduction in Psoriasis Area and Severity Index score relative to baseline;
 placebo ! tofacitinib 10 mg BID.
tor sites, non-responder imputation for missing values.
facitinib 10 mg BID, n = 38; placebo, n = 29.
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Fig. 4. Kaplan-Meier plots of the time maintaining PGA (A), PASI75 (B), and PASI90 (C) responses from Weeks 16 to 52 with tofacitinib 5 mg and 10 mg BID, among those
patients with a corresponding Week 16 response (FAS observed case).
Event is loss of response. Proportion maintaining a response is: 1-proportion of loss of response. Missing values from patients who had not experienced an event were
assumed to be right censored at the relevant time point using the last known data. BID, twice daily; FAS, full analysis set; PASI75, 75% reduction in Psoriasis Area and Severity
Index score relative to baseline; PASI90, 90% reduction in Psoriasis Area and Severity Index score relative to baseline; PGA, Physician’s Global Assessment.
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upper respiratory tract infection, nasopharyngitis, hyperlipidemia,
and increased blood cholesterol (Table S2).
Two serious infections (bronchopneumonia, tofacitinib 10 mg
BID; urinary tract infection, tofacitinib 5 mg BID) and two
malignancies (metastatic small-cell lung cancer, tofacitinib
10 mg BID; metastatic lung adenocarcinoma, tofacitinib 5 mg
BID) were reported (Table 3); both patients with malignancies
were current or ex-smokers.
In total, 11 herpes zoster cases were reported (tofacitinib 5 mg
BID, n = 3; tofacitinib 10 mg BID, n = 5; placebo advanced to
tofacitinib 5 mg BID, n = 1; placebo advanced to tofacitinib 10 mg
BID, n = 2); all were non-serious events that were categorized as
mild (n = 3) or moderate (n = 8) in severity (severe events, n = 0),
and all resolved without study treatment discontinuation. Four
multi-dermatomal herpes zoster cases were adjudicated as
opportunistic infections; no tuberculosis or other opportunistic
infections were reported.
No cases of MACE were reported. One death occurred in a
patient who received tofacitinib 5 mg BID, as a result of metastatic
lung adenocarcinoma (the same case as described above).
Over 52 weeks, small decreases from baseline in mean
lymphocyte count and neutrophil count were observed; no
patients experienced conﬁrmed (two consecutive measurements)
reductions in lymphocyte count <0.5 109/L or neutrophil count
<1.0  109/L (Fig. 5; Table S3). One patient receiving tofacitinib
10 mg BID had a conﬁrmed hemoglobin level reduction >30% from
baseline, which occurred after completing 52 weeks’ treatment. No
patients had conﬁrmed hemoglobin levels <10.0 g/dL. Small initial
mean increases in creatine phosphokinase were sustained over 52
weeks; no patient had conﬁrmed creatine phosphokinase >10 x the
upper limit of normal (ULN). Small mean increases from baseline in
low-density lipoprotein cholesterol (LDL-c) and high-density
lipoprotein cholesterol (HDL-c) were observed; there was no
change in mean LDL-c/HDL-c ratio. Conﬁrmed increases inTable 3
Summary of adverse events (all causality).
Weeks 0–16 Weeks 0–52 
Tofacitinib
5 mg BID
N = 88
Tofacitinib
10 mg BID
N = 90
Placeboa
N = 88
Tofacitinib 5 mg
BID N = 88
Tofacitinib 1
BID N = 90
Adverse events, n
(%)
57 (64.8) 61 (67.8) 43
(48.9)
74 (84.1) 76 (84.4) 
Serious adverse
events, n (%)
2 (2.3)b 0 0 4 (4.5)b,c 2 (2.2)d
Discontinuations
due to adverse
events, n (%)
3 (3.4) 1 (1.1) 3 (3.4) 3 (3.4) 1 (1.1) 
Deaths, n (%) 0 0 0 1 (1.1) 0 
Adverse events of special interest, n (%)
Serious infections 1 (1.1) 0 0 1 (1.1) 1 (1.1) 
Opportunistic
infectionsf
2 (2.3) 0 0 2 (2.3) 2 (2.2) 
Herpes zoster 2 (2.3) 3 (3.3) 0 3 (3.4) 5 (5.6) 
Malignancies 1 (1.1)g 0 0 1 (1.1)g 1 (1.1)h
MACE 0 0 0 0 0 
Gastrointestinal
perforation
0 0 0 0 0 
BID, twice daily; MACE, major adverse cardiovascular event.
a Placebo group includes patients randomized to placebo ! tofacitinib 5 mg BID and
b Urinary tract infection; lung adenocarcinoma metastatic.
c Arteriosclerosis coronary artery; ankle fracture.
d Bronchopneumonia; small-cell lung cancer metastatic.
e Arteriosclerosis coronary artery.
f All multi-dermatomal herpes zoster (non-adjacent dermatomes or >2 adjacent der
g Lung adenocarcinoma metastatic.
h Small-cell lung cancer metastatic.aspartate or alanine aminotransferase 3 x ULN were reported
in three patients who received tofacitinib 5 mg BID after
completion of the 52-week study treatment period. There were
no Hy’s Law cases.
4. Discussion
East Asian patients with psoriasis represent a distinct popula-
tion and have demonstrated differences in disease activity and
treatment outcomes compared with other regions [6]. Therefore, it
is important to examine the efﬁcacy and safety of potential
psoriasis therapies speciﬁcally in these patients.
In this study in patients from China mainland, Taiwan, and
Korea with moderate to severe psoriasis, both tofacitinib 5 mg and
10 mg BID were superior to placebo in the primary efﬁcacy
endpoints, PGA and PASI75 responses at Week 16. PGA and PASI75
responses at Week 16 were maintained in the majority of patients
(73.6–84.9%) through Week 52. In addition, tofacitinib 10 mg BID
was superior to placebo for all key secondary endpoints, while
tofacitinib 5 mg BID was superior to placebo for %CFB in BSA,
PASI90, and CFB in DLQI at Week 16, and PGA response at Week 4.
Tofacitinib 10 mg BID had a faster onset of effect and showed
greater efﬁcacy vs 5 mg BID.
Although no direct comparisons can be made, generally higher
PGA and PASI75 response rates were observed with tofacitinib
5 mg and 10 mg BID compared with the same doses in global
psoriasis studies [8–11]. This pattern is in line with results of a
regional Japanese study of tofacitinib [22], and reports of several
biologic agents [6]. Higher response rates in East Asian populations
may be due to differences in patient characteristics, including
lower body weight, shorter disease duration, less prior use of
biologic therapies, and higher baseline disease severity compared
with global clinical study populations [6]. Patients in this study
generally had a lower body mass index than those in the globalWeeks 16–52
0 mg Tofacitinib 5 mg
BID N = 84
Tofacitinib 10 mg
BID N = 83
Placebo ! 5 mg
BID N = 39
Placebo ! 10 mg
BID N = 38
57 (67.9) 53 (63.9) 29 (74.4) 29 (76.3)
2 (2.4)c 2 (2.4)d 0 1 (2.6)e
0 0 1 (2.6) 0
1 (1.2) 0 0 0
0 1 (1.2) 0 0
0 2 (2.4) 0 0
1 (1.2) 2 (2.4) 1 (2.6) 2 (5.3)
0 1 (1.2)h 0 0
0 0 0 0
0 0 0 0
 placebo ! tofacitinib 10 mg BID.
matomes); events also included in herpes zoster rates.
Fig. 5. Mean changes in laboratory parameters over time through Week 52.
BID, twice daily; CFB, change from baseline; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; SE, standard error.
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patients [8–10].
The overall safety proﬁle of tofacitinib in this study was
generally consistent with that observed in the global studies [8–
11]. The rates of most AEs of special interest were comparable with
those reported in the global studies [8–11]. However, the rate of
herpes zoster in this East Asian study population (11 cases in total
[9 China mainland, 2 Taiwan]; 4.3% of all patients, 3.1% of those
receiving tofacitinib 5 mg BID from Weeks 0 to 52 and 5.5% of those
receiving 10 mg BID from Weeks 0 to 52) appeared to be higher
than observed in the global psoriasis studies (0.8–1.5%) [11], but
was lower than that reported with tofacitinib in a study in Japanese
patients with psoriasis (17.0%) [22]. Background incidence of
herpes zoster is higher in Korea (10.4/1000 patient-years) [23]
compared with the global population (4.0–4.5/1000 patient-years)
[24], however annual incidence is similar in certain China
mainland regions (3.4–5.8/1000 patient-years) [25,26], and Taiwan
(5.0/1000 patient-years) [27]. An increased incidence rate of
herpes zoster in tofacitinib-treated patients from Japan and Korea,
compared with other regions, has been reported in previous global
studies of tofacitinib in psoriasis and RA [28–30]. No association
between Asian race and increased risk of herpes zoster has been
reported with other psoriasis therapies [31]. However, the reasons
for increased risk of herpes zoster remain undetermined.Two malignancies were reported, one of which resulted in
death, both in patients who were smokers. An analysis of
malignancies reported in clinical trials of tofacitinib in patients
with RA, which included 5671 patients with up to 72 months of
exposure, indicated that the overall incidence rates (IRs),
standardized IRs (SIRs; comparison with Surveillance, Epidemiol-
ogy and End Results program), and types of malignancies, most
commonly lung cancer, remained stable over time with increasing
tofacitinib exposure; SIRs in tofacitinib-treated patients were
within the range expected for patients with moderate to severe RA
[32].
Limitations to this study include the lack of placebo arm beyond
Week 16 and the lack of any active comparator control arm
throughout the study. In addition, although the 52-week study
duration and study population size were large enough to show
common AEs, accurate assessment of the frequency of rare or
uncommon AEs or those with long latency (e.g. malignancy or
cardiovascular AEs) may require a larger sample size and longer
timeframe; longer-term safety data for global studies of tofacitinib
have been published up to 33 months in psoriasis [11] and up to 8
years in RA [33]. As this was not a head-to-head study comparing
efﬁcacy between global and East Asian patients, no formal
statistical comparisons were made and therefore only general
indirect observations are possible. Finally, it is unclear how
44 J.Z. Zhang et al. / Journal of Dermatological Science 88 (2017) 36–45applicable the results from this study are to East Asian patients
living outside the region.
In summary, tofacitinib demonstrated efﬁcacy vs placebo in
patients in East Asia with moderate to severe psoriasis at Week 16,
which was maintained through Week 52. SAEs were infrequent
and no unexpected safety ﬁndings were observed compared with
previous tofacitinib studies in global populations.
Clinical trial registration
Clinicaltrials.gov: NCT01815424; Registered, March 18, 2013;
First patient ﬁrst visit, December 12, 2013
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